Yarrow Bioscience, Inc. YARW
Biotechnology: Pharmaceutical Preparations · IPO 2018 · data as of November 13, 2026
Yarrow Bioscience, Inc. (YARW) is a healthcare company listed in the US with a market value of about $207M. In the twelve months to June 30, 2026 it had revenue of $482000 and net income of —.
Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of -51% a year, a 5-year average ROIC of -70%.
About Yarrow Bioscience
Yarrow Bioscience is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2018. Revenue went from $674000 in 2016 to $570000 in 2025, a decline of about 1.8% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 1242% over three years (dilution for shareholders). It spends 3375% of revenue on research and development.
Score: 1.4 / 5
Checks passed
- Revenue growth above 10% last year
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $482000 | $570000 | $501000 | $424000 | $477000 | $931000 | $21M | $443000 | $4M | $5M | $674000 |
| Net income | — | -$26M | -$40M | -$28M | -$23M | -$73M | -$256M | -$95M | -$74M | -$29M | -$14M |
| Free cash flow | — | -$33M | -$34M | -$25M | — | -$56M | -$137M | -$74M | -$69M | -$28M | -$2M |
| EPS (diluted) | $8.61 | $-0.62 | $-0.93 | $-2.78 | $-7.28 | $-25.64 | $141.86 | $201.99 | $206.49 | $-102.43 | $-50.77 |
| Net margin | — | -4646.1% | -7950.9% | -6710.4% | -4865.8% | -7876.4% | -1217.4% | -21484.9% | -2062.9% | -634.6% | -2087.2% |
| ROIC | — | -84.7% | -66.1% | -32.9% | -86.8% | -78.6% | -349.1% | -183.9% | -64.2% | -34.1% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 3 analysts is $57.33, 218% above the current price; targets range from $54.00 to $60.00; the consensus rating is “Strong buy”; expected EPS is $-1.45 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Yarrow Bioscience pay a dividend?
Not currently.
Is Yarrow Bioscience a good stock to buy?
We do not give buy or sell advice. Yarrow Bioscience scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.